On the stock market since 2012, it operates in the world of health and science. It has 179 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
If every debt were paid off today, $69.0M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $97.5M in the vault; even if every debt were paid off, $69.0M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 3 years, sales grew only 0% a year on average. At this size, speeding back up is not easy.
On our five-subject report card, PBYI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PBYI is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.